Abstracts tagged "anti-TNF therapy"

Abstract Number: 2758 • 2015 ACR/ARHP Annual Meeting
Clinical Utility and Factors Associated with Certolizumab Pegol Drug Levels and Anti-Drug Antibodies in the Long-Term Treatment of Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, John Isaacs³, Ann W. Morgan⁴, Anthony Wilson⁵, Kimme L. Hyrich⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, ⁶Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose: Up to 40% of RA patients on anti-TNF agents fail to respond either due to primary or secondary inefficacy. One explanation is immunogenicity leading…
Abstract Number: 2879 • 2015 ACR/ARHP Annual Meeting
What Is the Location of Dactylitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?
Regan Arendse¹, Proton Rahman², Denis Choquette³, J Antonio Avina-Zubieta⁴, Michel Zummer⁵, Milton F. Baker⁶, Jacqueline Stewart⁷, Isabelle Fortin⁸, Michelle Teo⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Brendan Osborne¹², Cathy Tkaczyk¹², Karina Maslova¹³, Francois Nantel¹⁴ and Allen J Lehman¹³, ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, ³Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁵Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ⁶VIHA, Victoria, BC, Canada, ⁷Penticton Regional Hospital, Penticton, BC, Canada, ⁸Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁹Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Dactylitis is one of the most commonly reported features in spondyloarthritis. It has been hypothesized that dactylitis is a functional enthesitis at the proximal…
Abstract Number: 446 • 2015 ACR/ARHP Annual Meeting
Low Disease Activity at 12 Weeks and 24 Weeks Is Predictive of Normalized Health-Related Quality of Life in Methotrexate-Experienced Patients with Active Rheumatoid Arthritis Treated with Intravenous Golimumab Plus Methotrexate
Clifton O. Bingham III¹, Michael Weinblatt², Rene Westhovens³, Lilianne Kim⁴, Chenglong Han⁵, Stephen Xu⁴, Kim Hung Lo⁴, Kezhen L. Tang⁴, Elizabeth C. Hsia^4,6, Dennis Parenti⁷ and Shelly Kafka⁷, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Brigham and Women's Hospital, Boston, MA, ³UZ Gasthuisberg, Leuven, Belgium, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Global Services, LLC, Malvern, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Previous analyses in patients (pts) with rheumatoid arthritis (RA) have evaluated the relationship between controlling disease activity and achieving long-term improvements in health-related quality…
Abstract Number: 701 • 2015 ACR/ARHP Annual Meeting
Is Skin Disease More Important to Women or Men in the Assessment of Disease Activity in Psoriatic Arthritis?
Maqbool Sheriff¹, Michel Zummer², J Antonio Avina-Zubieta³, Proton Rahman⁴, Wojciech Olszynski⁵, Michael Starr⁶, Philip Baer⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Cathy Tkaczyk¹⁰, Brendan Osborne¹⁰, Karina Maslova¹¹, Francois Nantel¹² and Allen J Lehman¹¹, ¹Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ²Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ³Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁴Rheumatology, St. Clare's Mercy Hospital, St. John's, NF, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶Rheumatology, McGill University, Montreal, QC, Canada, ⁷Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Patient global assessment of disease activity (PtGA) is a standard outcome measure used both in randomized controlled trials and in clinical practice to ascertain…
Abstract Number: 1700 • 2015 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis in Ankylosing Spondylitis. Does It Really Exist and Which Are the Effects of Treatments? a Systematic Review
Clément Prati¹, Céline Demougeot², Xavier Guillot² and Daniel Wendling³, ¹Service de Rhumatologie, CHRU J Minjoz, Besançon, France, ²EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche-Comté, Besançon, France, ³Université de Franche-Comté, Besançon, France
Background/Purpose: Accelerated atherosclerosis and increased cardiovascular morbidity and mortality have been associated with ankylosing spondylitis (AS). Noninvasive angiological methods have been developped to evaluate endothelial…
Abstract Number: 2768 • 2015 ACR/ARHP Annual Meeting
Trend and Factors Associated with Switching Treatment after Initial Anti-TNF Therapy Among Patients with Rheumatoid Arthritis
Wenhui Wei¹, Emma Sullivan², Chieh-I Chen³, James Piercy² and Stuart Blackburn², ¹Sanofi-Aventis, Bridgewater, NJ, ²Adelphi Real World, Manchester, United Kingdom, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Among rheumatoid arthritis (RA) patients who progress beyond their first biologic disease-modifying antirheumatic drug (bDMARD), in-class cycling between different tumor necrosis factor inhibitors (TNFi)…
Abstract Number: 2893 • 2015 ACR/ARHP Annual Meeting
Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis after 16 Weeks of Golimumab Treatment
Walter Maksymowych¹, Sean P. Curtis², Maxime Dougados³, Gina Bergman², Susan Huyck², Anjela Tzontcheva² and Joachim Sieper⁴, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Merck & Co., Inc., Kenilworth, NJ, ³Paris-Descartes University, Paris, France, ⁴University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: Chronic inflammation, back pain, and progressive spinal stiffness associated with axial spondyloarthritis (axSpA) can decrease quality of life (QoL). The purpose of this study…
Abstract Number: 2427 • 2014 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Katsutoshi Hiramatsu⁶, Aki Kuroki⁵ and Tsutomu Takeuchi⁷, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie, Tokyo, Japan, ⁶Medical, Abbvie, Tokyo, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Although available data has suggested successful withdrawal of a monoclonal antibody TNF blocker after achieving low disease activity (LDA) or remission over the short-term…
Abstract Number: 956 • 2014 ACR/ARHP Annual Meeting
Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Proton Rahman¹, Saeed Shaikh², Michael Starr³, William Bensen⁴, Denis Choquette⁵, Wojciech Olszynski⁶, Maqbool Sheriff⁷, Michel Zummer⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, Allen J Lehman¹⁰, Susan Otawa¹⁰, Francois Nantel¹¹, Vincent Letourneau¹¹ and May Shawi¹¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²McMaster University, Hamilton, ON, Canada, ³Montreal General Hospital, Montreal, QC, Canada, ⁴Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸Université de Montréal, Montreal, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose A definition of minimal disease activity (MDA) in PsA was derived from the opinion of 60 PsA experts including fulfillment of ≥5 of the…
Abstract Number: 519 • 2014 ACR/ARHP Annual Meeting
Patterns of Tocilizumab Use and Safety in Patients with Rheumatoid Arthritis: Interim Results from a Multinational Observational Study
Boulos Haraoui¹, Gustavo Casado², Elke Theander³, Laszlo Czirják⁴, Andrew Taylor⁵, Peter Button⁶, Lykke Hinsch Gylvin⁷ and Roberto Caporali⁸, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Hospital Militar Central, Buenos Aires, Argentina, ³Skane University Hospital Malmö, Lund University, Malmö, Sweden, ⁴University of Pécs, Pécs, Hungary, ⁵Royal Perth Hospital, Perth, Australia, ⁶Roche Products Pty Limited, Dee Why, Australia, ⁷F. Hoffmann-La Roche, Basel, Switzerland, ⁸Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Background/Purpose: Tocilizumab (TCZ) is indicated for the treatment of patients with RA who have had inadequate responses to DMARDs either as monotherapy (Mono) or in…
Abstract Number: 2343 • 2014 ACR/ARHP Annual Meeting
Therapeutic Effects of Mesenchymal Stem Cells, Anti-Tumor Necrosis Factor and Anti-CD20 Treatment on Collagen Induced Arthritis
Yue Sun¹, Xuebing Feng² and Lingyun Sun², ¹The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose Tremendous progress has been made in the development of non-conventional therapies for rheumatoid arthritis (RA). In this study, the effects of mesenchymal stem cells…
Abstract Number: 934 • 2014 ACR/ARHP Annual Meeting
Amelioration of Inflammatory Arthritis By Anti-TNF Therapy Is Associated with Restoration of Lymphatic Contraction
Echoe M. Bouta¹, Igor Kuzin², Karen de Mesy-Bentley¹, Ronald Wood³, Homaira Rahimi⁴, Rui-Cheng Ji⁵, Christopher T. Ritchlin⁶, Andrea Bottaro², Lianping Xing⁷ and Edward M. Schwarz⁸, ¹University of Rochester, Rochester, NY, ²Cooper Medical School, Camden, NJ, ³Department of Urology, University of Rochester Medical Center, Rochester, NY, ⁴Rheumatology, University of Rochester/Golisano Children's Hospit, Rochester, NY, ⁵Department of Anatomy, Biology and Medicine, Oita University, Oita, Japan, ⁶Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁷Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁸Center for Musculoskeletal Research, University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with episodic flares. In tumor necrosis factor transgenic (TNF-Tg) mice, a model of inflammatory-erosive arthritis,…
Abstract Number: 479 • 2014 ACR/ARHP Annual Meeting
Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results through 2 Years
Rene Westhovens¹, Edward C. Keystone², Clifton O. Bingham III³, Elizabeth C. Hsia^4,5, Lilianne Kim⁴, Yiying Zhou⁴, Alan M. Mendelsohn⁶ and Michael E. Weinblatt⁷, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Johns Hopkins University, Baltimore, MD, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁷Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA
Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results through 2 Years Background/Purpose: To describe the safety profile…
Abstract Number: 2203 • 2014 ACR/ARHP Annual Meeting
Adalimumab Therapy Improves Insulin Sensitivity in Non-Diabetic Psoriatic Patients: A 6-Month Prospective Study
Trinitario Pina Murcia¹, Raquel López-Mejías¹, Fernanda Genre¹, Begoña Ubilla¹, Susana Armesto², Marcos A. González-López², María del Carmen Gonzalez-Vela³, Javier Llorca⁴, Ricardo Blanco⁵ and MA González-Gay¹, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Dermatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Dept. of Pathology, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁵Hospital Marques de Valdecilla, Santander, Spain
Background/Purpose: psoriasis is a systemic inflammatory condition that shares similarities with other inflammatory immune disorders. In this context, patients with psoriasis are at an increased…
Abstract Number: 932 • 2014 ACR/ARHP Annual Meeting
MRP8/14 Serum Level As Predictor of Response to Starting and Stopping Anti-TNF Treatment in Non-Systemic Juvenile Idiopathic Arthritis
Janneke Anink¹, Marieke H. Otten¹, Lisette W.A. van Suijlekom-Smit¹, Marion A.J. Van Rossum², Koert M. Dolman³, Esther P.A. Hoppenreijs⁴, Rebecca ten Cate⁵, Simona Ursu⁶, Lucy R Wedderburn⁷, Gerd Horneff⁸, Thomas Vogl^9,10, Dirk Föll^10,11, Johannes Roth^9,12 and Dirk Holzinger^10,13, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Pediatric Rheumatology, Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, ³Pediatric Rheumatology, St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands, ⁴Pediatric Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁵Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁷Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁹Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ¹⁰Interdisciplinary Centre for Clinical Research IZKF, University Hospital Muenster, Muenster, Germany, ¹¹Pediatric Rheumatology and Immunology, University Children's Hospital Muenster, Muenster, Germany, ¹²University Hospital Muenster, Muenster, Germany, ¹³Pediatric Rheumatology and Immunology, University Children’s Hospital Muenster, Muenster, Germany
Background/Purpose: Biological therapy has dramatically improved the treatment of patients with JIA. However, there is still a group of patients that shows a lack of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.